WO2011031100A2 - Aripiprazole-bentonite-aea hybrid, pharmaceutical composition containing the same and method for preparing the same - Google Patents

Aripiprazole-bentonite-aea hybrid, pharmaceutical composition containing the same and method for preparing the same Download PDF

Info

Publication number
WO2011031100A2
WO2011031100A2 PCT/KR2010/006193 KR2010006193W WO2011031100A2 WO 2011031100 A2 WO2011031100 A2 WO 2011031100A2 KR 2010006193 W KR2010006193 W KR 2010006193W WO 2011031100 A2 WO2011031100 A2 WO 2011031100A2
Authority
WO
WIPO (PCT)
Prior art keywords
aripiprazole
hybrid
aea
bentonite
pharmaceutical composition
Prior art date
Application number
PCT/KR2010/006193
Other languages
French (fr)
Other versions
WO2011031100A3 (en
Inventor
Jin Ho Choy
Yeon Ji Oh
Myung Chul Park
Hee Chul Chang
Original Assignee
Daewoong Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co., Ltd. filed Critical Daewoong Pharmaceutical Co., Ltd.
Publication of WO2011031100A2 publication Critical patent/WO2011031100A2/en
Publication of WO2011031100A3 publication Critical patent/WO2011031100A3/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Definitions

  • the present invention relates to an aripiprazole-bentonite-AEA hybrid, a pharmaceutical composition containing the same and a method for preparing the same. More preferably, in the aripiprazole-bentonite-AEA hybrid according to the present invention, aripiprazole is incorporated between the layers of bentonite, and AEA polymer is coated on the hybrid.
  • Psychiatric diseases and disorders are described in publications such as the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders.
  • the broad scope of mental disorders include, but is not limited thereto, mood disorder, anxiety disorder, schizophrenia and other psychotic disorders, substance-related disorder, sleep disorder, somatoform disorder and eating disorder.
  • mood disorder include bipolar disorder and depression.
  • Such disorders infiltrate millions of people and are marantic diseases which entail enormous cost in terms of medical treatment, loss of productivity and emotional sacrifice.
  • drugs for treating psychiatric illness and treating methods have been continuously developed.
  • a representative drug for treating psychiatric illness is aripiprazole, an atypical psychotropic that acts on the central nervous system.
  • Korean Laid-Open Patent Application Publication No. 2005-0040927 discloses an aripiprazole inclusion complex with a substituted ß-cyclodextrin, an aripiprazole formulation which includes aripiprazole in the form of the above inclusion complex, an injectable formulation which contains the above complex of aripiprazole, a method for reducing irritation normally caused by aripiprazole at an intramuscular injection site employing the above injectable formulation and a method for treating schizophrenia employing the above formulation.
  • Korean Laid-Open Patent Application Publication No. 2006-0118450 discloses a controlled-release sterile freeze-dried aripiprazole formulation which releases aripiprazole over at least a one-week period.
  • the object of the present invention is to provide an aripiprazole-bentonite-AEA hybrid, a pharmaceutical composition for treating psychiatric illness containing the same and a method for preparing the same.
  • the present inventors performed intensive studies for developing a formulation by which aripiprazole, which is needed to treat psychiatric illness, is administered more easily and thus drug-administration compliance is increased, and shows high bioavailability through a rapid dissolution rate.
  • a hybrid obtained by incorporating aripiprazole between the layers of bentonite, which is a pharmaceutical excipient used as a thickener or an inorganic carrier, and then coating with AEA (polyvinyl acetal-diethyl amino-acetate) polymer, which is a gastric coating blocks the bitter taste of ursodeoxycholic acid and simultaneously shows an improved dissolution rate and high bioavailability; thus they completed the present invention.
  • AEA polyvinyl acetal-diethyl amino-acetate
  • an aripiprazole-bentonite-AEA hybrid represented by the following Formula 1 and a pharmaceutical composition for treating psychiatric illness comprising the same as an active ingredient:
  • A is AEA (polyvinyl acetal-diethyl amino-acetate);
  • x is 0.2 to 0.7
  • y is a positive number above 0.
  • the present invention also provides a method for preparing an aripiprazole-bentonite-AEA hybrid comprising the steps of: (a) dissolving aripiprazole in purified water to prepare a solution containing aripiprazole; (b) mixing and stirring the solution containing aripiprazole prepared in step (a) with an aqueous solution in which bentonite is dispersed to prepare a hybrid in which aripiprazole is incorporated between the layers of bentonite; and (c) spray-drying AEA (polyvinyl acetal-diethyl amino-acetate) to said hybrid to prepare an AEA-coated hybrid.
  • AEA polyvinyl acetal-diethyl amino-acetate
  • the present invention also provides a method for preparing a pharmaceutical composition for treating psychiatric illness comprising the steps of: (a) dissolving aripiprazole in purified water to prepare a solution containing aripiprazole; (b) mixing and stirring the solution containing aripiprazole prepared in step (a) with an aqueous solution in which bentonite is dispersed to prepare a hybrid in which aripiprazole is incorporated between the layers of bentonite; (c) spray-drying AEA (polyvinyl acetal-diethyl amino-acetate) to said hybrid to prepare an AEA-coated hybrid; and (d) formulating said coated hybrid to various formulations according to pharmaceutically acceptable formulas and processes.
  • AEA polyvinyl acetal-diethyl amino-acetate
  • the formulation comprising a hybrid according to the present invention shows increased treating effects for psychiatric illness because of increased bioavailability via the improvement of solubilization and dissolution rate, and the enhanced administration convenience and administration compliance.
  • Figure 1 is a graph showing the dissolution rate in artificial gastric juice (pH 1.2) according to a paddle method (a: aripiprazole-bentonite-AEA hybrid, b: aripiprazole-bentonite hybrid, c: AbilifyTM tablet).
  • Figure 2 is a concentration-time graph of aripiprazole according to a pharmacokinetic test (a: aripiprazole-bentonite-AEA hybrid, b: AbilifyTM tablet).
  • the present invention relates to an aripiprazole-bentonite-AEA hybrid represented by the following Formula 1 and a pharmaceutical composition for treating psychiatric illness comprising the same as an active ingredient:
  • A is AEA (polyvinyl acetal-diethyl amino-acetate);
  • x is 0.2 to 0.7
  • y is a positive number above 0.
  • hybrid refers to a form in which aripiprazole is incorporated between the layers of bentonite and bound by electrostatic attraction.
  • hybrid as above also includes a form in which AEA polymer is coated on the hybrid by electrostatic attraction.
  • “comprising X as an active ingredient” means that ingredient X is comprised to an extent that would show any medical or pharmacological effects of influences on psychiatric illness such as treatment of psychiatric illness, alleviation of some symptoms, etc.
  • aripiprazole (7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone) represented by the following Formula 2 is an atypical psychotropic to be used for treating a broad range of psychiatric illnesses including schizophrenia, mood disorder, anxiety disorder and other psychotic disorders by acting on the central nervous system, and has an intrinsic bitter taste.
  • psychiatric illness means that generally can be treated by the administration of aripiprazole, and refers to nervous disease, neuropsychiatric disease and neurodegenerative disease.
  • psychiatric illness includes schizophrenia, bipolar disorder, autism, attention deficit hyperactivity disorder, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, panic, obsessive-compulsive disorder, etc.
  • Bentonite represented by the following Formula 3 is a naturally existing inorganic mineral and is used in suspension preparation, ointment preparation, toothpaste, etc.
  • Bentonite containing many calcium ions is a pharmaceutical excipient and comprised in a pharmaceutical composition such as antidote, a medicine for the stomach and bowels as a thickener, inorganic carrier, etc.
  • M is an interlayer ion which may be substituted with cationic organic material
  • x is a compositional ratio of interlayer ion having a value of 0.2 to 0.7;
  • n is valence
  • AEA is polyvinyl acetal-diethyl amino-acetate based polymer used as a gastric coating, and can improve body absorption and bioavailability.
  • the present composition may further comprise a dissolution aid.
  • dissolution aids include various surfactants such as pharmaceutically acceptable anionic, cationic, nonionic or zwitterionic surfactants. More specifically, examples of surfactants include polyoxyethylene sorbitan fatty acid ester, sorbitan fatty acid ester, polyoxyethylene fatty acid ester and the like.
  • the above pharmaceutical composition may further comprise pharmaceutically acceptable additives.
  • the additives may be selected from the group consisting of excipient, disintegrant, binder, glidant, lubricant, suspending agent, surfactant, sweetener, preservative, flavor, thickener, pH regulator, wetting agent and mixture thereof.
  • the hybrid may be a hybrid in which said aripiprazole is incorporated between the layers of bentonite and AEA is coated.
  • the coating may be carried out by spray-drying.
  • the present invention relates to a method for preparing aripiprazole-bentonite-AEA hybrid comprising the steps of: (a) dissolving aripiprazole in purified water to prepare a solution containing aripiprazole; (b) mixing and stirring the solution containing aripiprazole prepared in step (a) with an aqueous solution in which bentonite is dispersed to prepare a hybrid in which aripiprazole is incorporated between the layers of bentonite; and (c) spray-drying AEA to said hybrid to prepare an AEA-coated hybrid.
  • the aripiprazole-bentonite hybrid of the above steps (a) and (b) is preferably prepared by an ion-exchange method.
  • concentration of bentonite-dispersed solution is, for example, 0.01 to 10% by weight, and that of aripiprazole-dissolved solution is, for example, 0.01 to 50% by weight.
  • Acidic solution to be added may be selected from the group consisting of hydrochloric acid, nitric acid, sulfuric acid and phosphoric acid, and the pH of the prepared acidic solution containing aripiprazole is preferably 2 to 4.
  • the amount of aripiprazole in the above step (b) is, for example, about 0.1 to 10 molar ratio based on moles of bentonite.
  • the coating of AEA in step (c) may be carried out by dispersing the hybrid in a solution containing AEA and then drying it. It is preferable to use spray-drying for good uniformity. Spray-drying is advantageous in that the drying is fast, and fine particles below 100 microns can be made.
  • the content of aripiprazole in the aripiprazole-bentonite hybrid of the above step (b) and the aripiprazole-bentonite-AEA hybrid of the above step (c) is preferably 1 to 50% by weight.
  • the present invention relates to a method for preparing a pharmaceutical composition for treating psychiatric illness comprising the steps of: (a) dissolving aripiprazole in purified water to prepare a solution containing aripiprazole; (b) mixing and stirring the solution containing aripiprazole prepared in step (a) with an aqueous solution in which bentonite is dispersed to prepare a hybrid in which aripiprazole is incorporated between the layers of bentonite; (c) spray-drying AEA to said hybrid to prepare an AEA-coated hybrid; and (d) formulating said coated hybrid to various formulations according to pharmaceutically acceptable formulas and processes.
  • the aripiprazole-bentonite-AEA hybrid according to the present invention may be prepared as a pharmaceutical composition for treating psychiatric illness of all pharmaceutical formulations such as powder, granule, capsule, tablet, suspension, chewable tablet, oral soluble film formulation, oral disintegrating tablet, syrup, dry syrup, etc. through various conventionally known formulation steps.
  • the preferable unit dose of pharmaceutical composition for treating psychiatric illness according to the present invention varies depending on factors such as age, sex, etc. of the administration subject but is generally 2 to 60 mg, preferably 5 to 30 mg based on the amount of aripiprazole.
  • the unit dose refers to the amount of medicament administered to an adult per day and may be administered in a single dose or divided several times.
  • the pharmaceutical composition for treating psychiatric illness according to the present invention may be orally administered one time or divided into three times per day.
  • the present pharmaceutical composition for treating psychiatric illness may further comprise a mood stabilizer such as lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam, clonazepam or salts thereof.
  • a mood stabilizer such as lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam, clonazepam or salts thereof.
  • the dissolution test of the aripiprazole-bentonite-AEA hybrid prepared in the above Example 1, aripiprazole-bentonite-AEA hybrid (comparative group) and AbilifyTM tablet (control group) was carried out according to the Korean Pharmacopeia apparatus 2 for dissolution test (paddle method).
  • the dissolution solution was prepared according to artificial gastric juice composition (pH 1.2), paddle velocity was 50 rpm, and the temperature of the dissolution solution was 37°C. Test samples were filtered and then quantitative analysis was carried out under conditions of the following Table 1. The results are represented in Figure 1.
  • the dissolution of aripiprazole from the aripiprazole-bentonite-AEA hybrid was 80% within 10 minutes and 95% within 120 minutes as similar to the AbilifyTM tablet used as a control group.
  • Such a dissolution pattern is much higher than that of the aripiprazole-bentonite hybrid which is not coated with AEA, and such effect derived from AEA which is a gastric coating dissolved only in acidic condition.
  • the aripiprazole-bentonite-AEA hybrid according to the present invention showed parameters equivalent to those of control or more in all statistical results and high bioavailability.
  • the present aripiprazole-bentonite-AEA hybrid can effectively treat psychiatric illness.
  • Example 2 Preparation of pharmaceutical composition for treating psychiatric illness comprising aripiprazole-bentonite-AEA hybrid
  • the pharmaceutical composition comprising an aripiprazole-bentonite-AEA hybrid as a main ingredient was prepared with ingredients as listed in the following Table 4.
  • Beta-cyclodextrin was dissolved in purified water, and then the aripiprazole-bentonite-AEA hybrid (main ingredient) and excipients were added thereto and dried. Powder (1,000 mg/package) was prepared according to a conventional method.
  • the pharmaceutical composition was prepared by the same method as described in Example 2 except that pure aripiprazole was used as the main ingredient.
  • the pharmaceutical composition comprising aripiprazole-bentonite-AEA hybrid prepared in the above Example 2 was orally administered to 30 healthy adults, and then the level of bitter taste was evaluated at 5 minutes after administration.
  • the evaluation results were divided into six (6) grades and are represented in the following Table 5.
  • the pharmaceutical composition comprising pure aripiprazole prepared in Comparative Example 1 was also tested.
  • the pharmaceutical composition comprising aripiprazole-bentonite-AEA hybrid can reduce adverse reaction at the time of oral administration and increase administration convenience by successfully blocking the bitter taste of aripiprazole.
  • the pharmaceutical composition for treating psychiatric illness comprising aripiprazole-bentonite-AEA hybrid according to the present invention shows rapid dissolution rate in a short time by the ion-exchange effect of AEA dissolved in artificial gastric juice as well as a good blocking effect against the bitter taste at sensory test.
  • the present pharmaceutical composition has good bioavailability, and thus is very useful industrially.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to an aripiprazole-bentonite-AEA hybrid, a pharmaceutical composition containing the same and a method for preparing the same. The aripiprazole-bentonite-AEA hybrid according to the present invention is very useful as an active ingredient of a pharmaceutical composition for treating psychiatric illness including schizophrenia and bipolar disorder because of its bitter-taste-blocking effect and improved body absorption rate with high solubility.

Description

ARIPIPRAZOLE-BENTONITE-AEA HYBRID, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND METHOD FOR PREPARING THE SAME
The present invention relates to an aripiprazole-bentonite-AEA hybrid, a pharmaceutical composition containing the same and a method for preparing the same. More preferably, in the aripiprazole-bentonite-AEA hybrid according to the present invention, aripiprazole is incorporated between the layers of bentonite, and AEA polymer is coated on the hybrid.
Psychiatric diseases and disorders (also known as psychosis or mental disorders) are described in publications such as the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders. The broad scope of mental disorders include, but is not limited thereto, mood disorder, anxiety disorder, schizophrenia and other psychotic disorders, substance-related disorder, sleep disorder, somatoform disorder and eating disorder. Examples of mood disorder include bipolar disorder and depression. Such disorders infiltrate millions of people and are marantic diseases which entail enormous cost in terms of medical treatment, loss of productivity and emotional sacrifice. As a result, drugs for treating psychiatric illness and treating methods have been continuously developed.
A representative drug for treating psychiatric illness is aripiprazole, an atypical psychotropic that acts on the central nervous system.
As examples of using aripiprazole for treating psychiatric illness, Korean Laid-Open Patent Application Publication No. 2005-0040927 discloses an aripiprazole inclusion complex with a substituted ß-cyclodextrin, an aripiprazole formulation which includes aripiprazole in the form of the above inclusion complex, an injectable formulation which contains the above complex of aripiprazole, a method for reducing irritation normally caused by aripiprazole at an intramuscular injection site employing the above injectable formulation and a method for treating schizophrenia employing the above formulation.
In addition, to improve the dissolution rate of aripiprazole, Korean Laid-Open Patent Application Publication No. 2006-0118450 discloses a controlled-release sterile freeze-dried aripiprazole formulation which releases aripiprazole over at least a one-week period.
The object of the present invention is to provide an aripiprazole-bentonite-AEA hybrid, a pharmaceutical composition for treating psychiatric illness containing the same and a method for preparing the same.
The present inventors performed intensive studies for developing a formulation by which aripiprazole, which is needed to treat psychiatric illness, is administered more easily and thus drug-administration compliance is increased, and shows high bioavailability through a rapid dissolution rate. As a result, they surprisingly found that a hybrid obtained by incorporating aripiprazole between the layers of bentonite, which is a pharmaceutical excipient used as a thickener or an inorganic carrier, and then coating with AEA (polyvinyl acetal-diethyl amino-acetate) polymer, which is a gastric coating, blocks the bitter taste of ursodeoxycholic acid and simultaneously shows an improved dissolution rate and high bioavailability; thus they completed the present invention.
Accordingly, to accomplish the above object the present invention provides an aripiprazole-bentonite-AEA hybrid represented by the following Formula 1 and a pharmaceutical composition for treating psychiatric illness comprising the same as an active ingredient:
[Formula 1]
(Al2-xMgx)(Si4)O10[OH]2[C23H27Cl2N3O2]x[A]y
wherein,
C23H27Cl2N3O2 is aripiprazole;
A is AEA (polyvinyl acetal-diethyl amino-acetate);
x is 0.2 to 0.7; and
y is a positive number above 0.
The present invention also provides a method for preparing an aripiprazole-bentonite-AEA hybrid comprising the steps of: (a) dissolving aripiprazole in purified water to prepare a solution containing aripiprazole; (b) mixing and stirring the solution containing aripiprazole prepared in step (a) with an aqueous solution in which bentonite is dispersed to prepare a hybrid in which aripiprazole is incorporated between the layers of bentonite; and (c) spray-drying AEA (polyvinyl acetal-diethyl amino-acetate) to said hybrid to prepare an AEA-coated hybrid.
The present invention also provides a method for preparing a pharmaceutical composition for treating psychiatric illness comprising the steps of: (a) dissolving aripiprazole in purified water to prepare a solution containing aripiprazole; (b) mixing and stirring the solution containing aripiprazole prepared in step (a) with an aqueous solution in which bentonite is dispersed to prepare a hybrid in which aripiprazole is incorporated between the layers of bentonite; (c) spray-drying AEA (polyvinyl acetal-diethyl amino-acetate) to said hybrid to prepare an AEA-coated hybrid; and (d) formulating said coated hybrid to various formulations according to pharmaceutically acceptable formulas and processes.
According to the present invention, because the intrinsic bitter taste of aripiprazole is blocked by the incorporation of aripiprazole between the layers of bentonite and the coating with AEA, adverse reaction at the time of oral administration is reduced, and aripiprazole is rapidly released in the gastrointestinal tract in a short time so as to increase bioavailability. The formulation comprising a hybrid according to the present invention shows increased treating effects for psychiatric illness because of increased bioavailability via the improvement of solubilization and dissolution rate, and the enhanced administration convenience and administration compliance.
Figure 1 is a graph showing the dissolution rate in artificial gastric juice (pH 1.2) according to a paddle method (a: aripiprazole-bentonite-AEA hybrid, b: aripiprazole-bentonite hybrid, c: Abilify™ tablet).
Figure 2 is a concentration-time graph of aripiprazole according to a pharmacokinetic test (a: aripiprazole-bentonite-AEA hybrid, b: Abilify™ tablet).
The present invention is described in detail hereinafter.
According to one aspect, the present invention relates to an aripiprazole-bentonite-AEA hybrid represented by the following Formula 1 and a pharmaceutical composition for treating psychiatric illness comprising the same as an active ingredient:
[Formula 1]
(Al2-xMgx)(Si4)O10[OH]2[C23H27Cl2N3O2]x[A]y
wherein,
C23H27Cl2N3O2 is aripiprazole;
A is AEA (polyvinyl acetal-diethyl amino-acetate);
x is 0.2 to 0.7; and
y is a positive number above 0.
The term “hybrid” used herein refers to a form in which aripiprazole is incorporated between the layers of bentonite and bound by electrostatic attraction. In addition, it should be understood that the term “hybrid” as above also includes a form in which AEA polymer is coated on the hybrid by electrostatic attraction.
In the present invention, “comprising X as an active ingredient” means that ingredient X is comprised to an extent that would show any medical or pharmacological effects of influences on psychiatric illness such as treatment of psychiatric illness, alleviation of some symptoms, etc.
In the present invention, “aripiprazole (7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone)” represented by the following Formula 2 is an atypical psychotropic to be used for treating a broad range of psychiatric illnesses including schizophrenia, mood disorder, anxiety disorder and other psychotic disorders by acting on the central nervous system, and has an intrinsic bitter taste.
[Formula 2]
Figure PCTKR2010006193-appb-I000001
In the present invention, “psychiatric illness” means that generally can be treated by the administration of aripiprazole, and refers to nervous disease, neuropsychiatric disease and neurodegenerative disease. For example, psychiatric illness includes schizophrenia, bipolar disorder, autism, attention deficit hyperactivity disorder, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, panic, obsessive-compulsive disorder, etc.
In the present invention, “bentonite” represented by the following Formula 3 is a naturally existing inorganic mineral and is used in suspension preparation, ointment preparation, toothpaste, etc. Bentonite containing many calcium ions is a pharmaceutical excipient and comprised in a pharmaceutical composition such as antidote, a medicine for the stomach and bowels as a thickener, inorganic carrier, etc.
[Formula 3]
(Al2-xMgx)(Si4)O10[OH]2M+n x/n
wherein,
M is an interlayer ion which may be substituted with cationic organic material;
x is a compositional ratio of interlayer ion having a value of 0.2 to 0.7; and
n is valence.
In the present invention, “AEA” is polyvinyl acetal-diethyl amino-acetate based polymer used as a gastric coating, and can improve body absorption and bioavailability.
Besides, the present composition may further comprise a dissolution aid. Examples of dissolution aids include various surfactants such as pharmaceutically acceptable anionic, cationic, nonionic or zwitterionic surfactants. More specifically, examples of surfactants include polyoxyethylene sorbitan fatty acid ester, sorbitan fatty acid ester, polyoxyethylene fatty acid ester and the like.
In the present invention, the above pharmaceutical composition may further comprise pharmaceutically acceptable additives. The additives may be selected from the group consisting of excipient, disintegrant, binder, glidant, lubricant, suspending agent, surfactant, sweetener, preservative, flavor, thickener, pH regulator, wetting agent and mixture thereof.
In the present invention, the hybrid may be a hybrid in which said aripiprazole is incorporated between the layers of bentonite and AEA is coated. The coating may be carried out by spray-drying.
According to another aspect, the present invention relates to a method for preparing aripiprazole-bentonite-AEA hybrid comprising the steps of: (a) dissolving aripiprazole in purified water to prepare a solution containing aripiprazole; (b) mixing and stirring the solution containing aripiprazole prepared in step (a) with an aqueous solution in which bentonite is dispersed to prepare a hybrid in which aripiprazole is incorporated between the layers of bentonite; and (c) spray-drying AEA to said hybrid to prepare an AEA-coated hybrid.
In the present invention, the aripiprazole-bentonite hybrid of the above steps (a) and (b) is preferably prepared by an ion-exchange method. The concentration of bentonite-dispersed solution is, for example, 0.01 to 10% by weight, and that of aripiprazole-dissolved solution is, for example, 0.01 to 50% by weight. Acidic solution to be added may be selected from the group consisting of hydrochloric acid, nitric acid, sulfuric acid and phosphoric acid, and the pH of the prepared acidic solution containing aripiprazole is preferably 2 to 4. The amount of aripiprazole in the above step (b) is, for example, about 0.1 to 10 molar ratio based on moles of bentonite.
In the present invention, the coating of AEA in step (c) may be carried out by dispersing the hybrid in a solution containing AEA and then drying it. It is preferable to use spray-drying for good uniformity. Spray-drying is advantageous in that the drying is fast, and fine particles below 100 microns can be made.
In the present invention, the content of aripiprazole in the aripiprazole-bentonite hybrid of the above step (b) and the aripiprazole-bentonite-AEA hybrid of the above step (c) is preferably 1 to 50% by weight.
According to still another aspect, the present invention relates to a method for preparing a pharmaceutical composition for treating psychiatric illness comprising the steps of: (a) dissolving aripiprazole in purified water to prepare a solution containing aripiprazole; (b) mixing and stirring the solution containing aripiprazole prepared in step (a) with an aqueous solution in which bentonite is dispersed to prepare a hybrid in which aripiprazole is incorporated between the layers of bentonite; (c) spray-drying AEA to said hybrid to prepare an AEA-coated hybrid; and (d) formulating said coated hybrid to various formulations according to pharmaceutically acceptable formulas and processes.
The aripiprazole-bentonite-AEA hybrid according to the present invention may be prepared as a pharmaceutical composition for treating psychiatric illness of all pharmaceutical formulations such as powder, granule, capsule, tablet, suspension, chewable tablet, oral soluble film formulation, oral disintegrating tablet, syrup, dry syrup, etc. through various conventionally known formulation steps.
The preferable unit dose of pharmaceutical composition for treating psychiatric illness according to the present invention varies depending on factors such as age, sex, etc. of the administration subject but is generally 2 to 60 mg, preferably 5 to 30 mg based on the amount of aripiprazole. The unit dose refers to the amount of medicament administered to an adult per day and may be administered in a single dose or divided several times. The pharmaceutical composition for treating psychiatric illness according to the present invention may be orally administered one time or divided into three times per day.
In addition, the present pharmaceutical composition for treating psychiatric illness may further comprise a mood stabilizer such as lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam, clonazepam or salts thereof.
Hereinafter, the present invention is explained in more detail with the following examples. However, it must be understood that the protection scope of the present invention is not limited to the examples.
Example 1: Preparation of aripiprazole-bentonite-AEA hybrid
1-1. Preparation of aripiprazole-bentonite hybrid
The solution in which bentonite (0.1 M) was dissolved in distilled water was mixed with aripiprazole citrate (0.15 M) dissolved solution (pH 2) and then stirred for 4 hours. Unreacted salt was removed by filtering under reduced pressure and washing to obtain a hybrid in which aripiprazole is incorporated between the layers of bentonite.
1-2. Preparation of aripiprazole-bentonite-AEA hybrid
The aripiprazole-bentonite hybrid prepared in the above step 1-1 was resuspended in a mixed solvent of ethanol and methylene chloride, and then AEA dissolved in methylene chloride was added thereto (bentonite : AEA = 1 : 1 weight ratio). The resulting solution was spray-dried to obtain an aripiprazole-bentonite-AEA hybrid.
Experimental Example 1: Comparative dissolution test
The dissolution test of the aripiprazole-bentonite-AEA hybrid prepared in the above Example 1, aripiprazole-bentonite-AEA hybrid (comparative group) and Abilify™ tablet (control group) (commercially available from Korea Otsuka Pharmaceutical Co., Ltd. or Bristol-Meyers Squibb Co.) was carried out according to the Korean Pharmacopeia apparatus 2 for dissolution test (paddle method). The dissolution solution was prepared according to artificial gastric juice composition (pH 1.2), paddle velocity was 50 rpm, and the temperature of the dissolution solution was 37℃. Test samples were filtered and then quantitative analysis was carried out under conditions of the following Table 1. The results are represented in Figure 1.
Table 1
Figure PCTKR2010006193-appb-T000001
As can be seen from Figure 1, the dissolution of aripiprazole from the aripiprazole-bentonite-AEA hybrid was 80% within 10 minutes and 95% within 120 minutes as similar to the Abilify™ tablet used as a control group. Such a dissolution pattern is much higher than that of the aripiprazole-bentonite hybrid which is not coated with AEA, and such effect derived from AEA which is a gastric coating dissolved only in acidic condition.
Experimental Example 2: Pharmacokinetic evaluation via animal test
To confirm that the aripiprazole-bentonite-AEA hybrid prepared in the above Example 1 is statistically equivalent to the commercially available Abilify™ tablet in bioavailability, an animal test was carried out with male Sprague-Dawley rats.
After oral administration of the aripiprazole-bentonite-AEA hybrid prepared in the above Example 1 and the Abilify™ tablet to rats, blood was collected at each hour. Plasma was separated from blood, and then the amount of aripiprazole in plasma was measured by using HPLC-ESI-MS/MS under the conditions of the following Table 2. The results are represented in Figure 2 and Table 3. The equivalence of bioavailability between the present hybrid and control drug was evaluated via a T-test, and area under the plasma level-time curve (AUCt), peak concentration (Cmax) and time to peak concentration (Tmax) were used as an evaluation index according to the bioequivalence test notified by the Korea Food and Drug Administration.
Table 2
Figure PCTKR2010006193-appb-T000002
Table 3
Figure PCTKR2010006193-appb-T000003
As can be seen from Figure 2 and Table 3, the aripiprazole-bentonite-AEA hybrid according to the present invention showed parameters equivalent to those of control or more in all statistical results and high bioavailability. Thus, it can be known that the present aripiprazole-bentonite-AEA hybrid can effectively treat psychiatric illness.
Example 2: Preparation of pharmaceutical composition for treating psychiatric illness comprising aripiprazole-bentonite-AEA hybrid
The pharmaceutical composition comprising an aripiprazole-bentonite-AEA hybrid as a main ingredient was prepared with ingredients as listed in the following Table 4.
Table 4
Figure PCTKR2010006193-appb-T000004
Beta-cyclodextrin was dissolved in purified water, and then the aripiprazole-bentonite-AEA hybrid (main ingredient) and excipients were added thereto and dried. Powder (1,000 ㎎/package) was prepared according to a conventional method.
Comparative Example 1: Preparation of pharmaceutical composition comprising pure aripiprazole
The pharmaceutical composition was prepared by the same method as described in Example 2 except that pure aripiprazole was used as the main ingredient.
Experimental Example 3: Evaluation of bitter-taste-blocking effect of pharmaceutical composition comprising aripiprazole-bentonite-AEA hybrid
The pharmaceutical composition comprising aripiprazole-bentonite-AEA hybrid prepared in the above Example 2 was orally administered to 30 healthy adults, and then the level of bitter taste was evaluated at 5 minutes after administration. The evaluation results were divided into six (6) grades and are represented in the following Table 5. For comparison, the pharmaceutical composition comprising pure aripiprazole prepared in Comparative Example 1 was also tested.
Table 5
Figure PCTKR2010006193-appb-T000005
As a result of sensory evaluation, it can be known that the pharmaceutical composition comprising aripiprazole-bentonite-AEA hybrid can reduce adverse reaction at the time of oral administration and increase administration convenience by successfully blocking the bitter taste of aripiprazole.
The pharmaceutical composition for treating psychiatric illness comprising aripiprazole-bentonite-AEA hybrid according to the present invention shows rapid dissolution rate in a short time by the ion-exchange effect of AEA dissolved in artificial gastric juice as well as a good blocking effect against the bitter taste at sensory test. In addition, at bioequivalence test, it can be known that the present pharmaceutical composition has good bioavailability, and thus is very useful industrially.
Hereinbefore, the present invention and its embodiments have been described in detail. However, it would be evident for a person skilled in the art that the scope of the present invention is not intended to be limited to the particular embodiments, and various modifications and variations can be made without departing from the spirit of the present invention.

Claims (7)

  1. An aripiprazole-bentonite-AEA hybrid represented by the following Formula 1:
    [Formula 1]
    (Al2-xMgx)(Si4)O10[OH]2[C23H27Cl2N3O2]x[A]y
    wherein,
    C23H27Cl2N3O2 is aripiprazole;
    A is AEA (polyvinyl acetal-diethyl amino-acetate);
    x is 0.2 to 0.7; and
    y is a positive number above 0.
  2. The aripiprazole-bentonite-AEA hybrid according to claim 1, wherein aripiprazole is incorporated between the layers of bentonite and AEA polymer is coated on the hybrid.
  3. A pharmaceutical composition for treating psychiatric illness comprising the aripiprazole-bentonite-AEA hybrid according to claim 1 or 2 as an active ingredient.
  4. The pharmaceutical composition for treating psychiatric illness according to claim 3 wherein the content of aripiprazole in the aripiprazole-bentonite-AEA hybrid is 1 to 50% by weight.
  5. The pharmaceutical composition for treating psychiatric illness according to claim 3 which further comprises a pharmaceutically acceptable additive.
  6. The pharmaceutical composition according to claim 5, wherein the pharmaceutically acceptable additive is selected from the group consisting of excipient, diluent, disintegrant, binder, glidant, lubricant, surfactant, sweetener, preservative, flavor, thickener, pH regulator, wetting agent and mixture thereof.
  7. A method for preparing an aripiprazole-bentonite-AEA hybrid comprising the steps of:
    (a) dissolving aripiprazole in purified water to prepare a solution containing aripiprazole;
    (b) mixing and stirring the solution containing aripiprazole prepared in step (a) with an aqueous solution in which bentonite is dispersed to prepare a hybrid in which aripiprazole is incorporated between the layers of bentonite; and
    (c) spray-drying AEA (polyvinyl acetal-diethyl amino-acetate) to said hybrid to prepare an AEA-coated hybrid.
PCT/KR2010/006193 2009-09-11 2010-09-10 Aripiprazole-bentonite-aea hybrid, pharmaceutical composition containing the same and method for preparing the same WO2011031100A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090086151A KR101125210B1 (en) 2009-09-11 2009-09-11 Aripiprazole-Bentonite-AEA Nanohybrid, Pharmaceutical Composition Containing the Same, and Method for Preparing the Same
KR10-2009-0086151 2009-09-11

Publications (2)

Publication Number Publication Date
WO2011031100A2 true WO2011031100A2 (en) 2011-03-17
WO2011031100A3 WO2011031100A3 (en) 2011-08-04

Family

ID=43732975

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/006193 WO2011031100A2 (en) 2009-09-11 2010-09-10 Aripiprazole-bentonite-aea hybrid, pharmaceutical composition containing the same and method for preparing the same

Country Status (2)

Country Link
KR (1) KR101125210B1 (en)
WO (1) WO2011031100A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101571670B1 (en) 2012-08-08 2015-11-25 주식회사 씨엠지제약 Formulation for orodispersible film comprising aripirazole
KR20160139704A (en) 2015-05-28 2016-12-07 주식회사 씨엠지제약 Formulation for orodispersible film comprising aripirazole, and method of preparing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040147606A1 (en) * 2001-05-25 2004-07-29 Yoichi Onuki Medicinal compositions
KR20060093240A (en) * 2005-02-21 2006-08-24 (주)나노하이브리드 A base forming drug - layerd silicate hybrid containing basic polymer and its synthesis method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017897A2 (en) * 2002-08-20 2004-03-04 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
ES2315721T5 (en) * 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulation of sterile controlled-release injectable aripiprazole and procedure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040147606A1 (en) * 2001-05-25 2004-07-29 Yoichi Onuki Medicinal compositions
KR20060093240A (en) * 2005-02-21 2006-08-24 (주)나노하이브리드 A base forming drug - layerd silicate hybrid containing basic polymer and its synthesis method

Also Published As

Publication number Publication date
KR20110028179A (en) 2011-03-17
KR101125210B1 (en) 2012-03-19
WO2011031100A3 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2014163400A1 (en) Pharmaceutical composition for parenteral administration, containing donepezil
WO2011120281A1 (en) Use of l-oxiracetam in manufacture of medicaments for preventing or treating cognitive dysfunction
AU2413099A (en) Novel suppository form comprising an acid-labile active compound
JP2021167355A (en) Oral and injectable formulation of tetracycline compound
WO2015016667A1 (en) Orally disintegrating film preparation containing donepezil or pharmaceutically acceptable salt thereof, and preparation method therefor
WO2015194923A1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
WO2021261837A1 (en) Oral pharmaceutical composition comprising nafamostat mesylate as active ingredient
WO2011031100A2 (en) Aripiprazole-bentonite-aea hybrid, pharmaceutical composition containing the same and method for preparing the same
WO2021101295A1 (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
WO2012148181A2 (en) Composition for the controlled-release of drugs
WO2021091333A1 (en) Microsphere for continuous release and method for manufacturing same
WO2020180093A2 (en) Oseltamivir-containing pharmaceutical composition
WO2014163215A1 (en) Pharmaceutical composition having masked bitter taste
CN114773336B (en) Free PLX5622 crystal form and preparation method thereof
WO2014157852A1 (en) Sustained-release medicinal composition containing eperisone as active ingredient
WO2021133051A1 (en) Microspheres comprising ropinirole, and injection composition comprising same
WO2014104844A1 (en) Microgranular formulation including coagulation unit comprising discontinuous phase and continuous phase
WO2015163689A1 (en) Active ingredient (i) containing composition and method for preparing same
WO2014030913A1 (en) Poly(4-hydroxybutyrate)-b-monomethoxy(polyethylene glycol) copolymer nanoparticles, production method for same and pharmaceutical composition for brain disorder treatment containing same as active ingredient
AU2003217704A1 (en) Diphenhydramine tannate compositions and methods of use
WO2023085503A1 (en) Microspheres comprising high-dose varenicline, method for preparing same, and pharmaceutical composition comprising same
WO2019107989A1 (en) Solid dispersion comprising fimasartan
HRP980461A2 (en) Pharmaceutical suspension comprising nevirapine hemihydrate
WO2019050259A1 (en) Microparticles comprising moxidectin, and preparation method therefor
WO2018186650A2 (en) Double composite tablet for oral administration containing tramadol and celecoxib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10815645

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10815645

Country of ref document: EP

Kind code of ref document: A2